EHA 2020 | Edition virtuelle

Communication orales LYSA ASCO 2020
C Herbaux

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA

 

Abstract

S Le Gouill

Ibrutinib, Venetoclax plus Obinutuzumab in newly diagnosed Mantle Cell Lymphoma Patients

 

Abstract